HIV cure: global overview of bNAbs’ patents and related scientific publications

References

• Mascola JR, Montefiori DC. The role of antibodies in HIV vaccines. Annu Rev Immunol. 2010;28:413–444.
   PubMed Web of Science ®Google Scholar
• Khan L, Kumar R, Thiruvengadam R, et al. Cross-neutralizing anti-HIV-1 human single chain variable fragments (scFvs) against CD4 binding site and N332 glycan identified from a recombinant phage library. Sci Rep. 2017;7:45163.
   PubMed Web of Science ®Google Scholar
• The International AIDS Vaccine Initiative(IAVI). Antibodies: treatment, prevention and cure? IAVI Report. 2016;20(4):1–20.
   Google Scholar
• Barouch DH, Stephenson KE, Borducchi EN, et al. Protective efficacy of a global HIV-1 mosaic vaccine against heterologous SHIV challenges in rhesus monkeys. Cell. 2013;155(3):531–539.
   PubMed Web of Science ®Google Scholar
• Fuchs SP, Desrosiers RC. Promise and problems associated with the use of recombinant AAV for the delivery of anti-HIV antibodies. Mol Ther Methods Clin Dev. 2016;3:16068.
   PubMed Web of Science ®Google Scholar
• McCoy LE, Burton DR. Identification and specificity of broadly neutralizing antibodies against HIV. Immunol Rev. 2017;275(1):11–20.
   PubMed Web of Science ®Google Scholar
• Smith K, Garman L, Wrammert J, et al. Rapid generation of fully human monoclonal antibodies specific to a vaccinating antigen. Nat Protoc. 2009;4(3):372–384.
   PubMed Web of Science ®Google Scholar
• Williams L D., Ofek G, Schätzle S, et al. Potent and broad HIV-neutralizing antibodies in memory B cells and plasma. Sci Immunol. 2017;2(7):eaal2200.
   PubMedGoogle Scholar
• Scheid JF, Mouquet H, Ueberheide B, et al. Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science. 2011;333:1633–1637.
   PubMed Web of Science ®Google Scholar
• Walker LM, Phogat SK, Chan-Hui PY, et al. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science. 2009;326:285–289.
   PubMed Web of Science ®Google Scholar
• Walker LM, Huber M, Doores KJ, et al. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature. 2011;47(7):466–470.
   Google Scholar
• -Wu X, Yang ZY, Li Y, et al. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science. 2010;329:856–861.
   PubMed Web of Science ®Google Scholar
• Trkola A, Purtscher M, Muster T, et al. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J Virol. 1996; 70: 1100–1108.
   PubMed Web of Science ®Google Scholar
• Burton DR, Barbas CF, Persson MA, et al. A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals. Proc Natl Acad Sci U S A. 1991;88:10134–10137.
   PubMed Web of Science ®Google Scholar
• Purtscher M, Trkola A, Gruber G, et al. A broadly neutralizing human monoclonal antibody against gp41 of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses. 1994;10:1651–1658.
   PubMed Web of Science ®Google Scholar
• Stiegler G, Kunert R, Purtscher M, et al. A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses. 2001;17:1757–1765.
   PubMed Web of Science ®Google Scholar
• Cheeseman HM, Olejniczak NJ, Rogers PM, et al. Broadly neutralizing antibodies display potential for prevention of HIV-1 infection of mucosal tissue superior to that of nonneutralizing antibodies. J Virol. 2017;91(1):e01762–16.
   PubMed Web of Science ®Google Scholar
• Kwong PD, Mascola JR. Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies. Immunity. 2012;37(3):412–425.
   PubMed Web of Science ®Google Scholar
• Huang J, Kang BH, Ishida E, et al. Identification of a CD4-binding-site antibody to HIV that evolved near-pan neutralization breadth. Immunity. 2016;45(5):1108–1121.
   PubMed Web of Science ®Google Scholar
• Huang J, Kang BH, Pancera M, et al. Broad and potent HIV-1 neutralization by a human antibody that binds the gp41-gp120 interface. Nature. 2014;515:138–142.
   PubMed Web of Science ®Google Scholar
• Huang J, Ofek G, Laub L, et al. Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature. 2012;491:406–412.
   PubMed Web of Science ®Google Scholar
• The International Aids Vaccine Initiative (IAVI). Producing an immune response comprises administering to a mammal a purified antibody–antigen complex useful as prophylactic and therapeutic vaccines for infectious diseases of AIDS or HIV, where the antigen is an HIV envelope protein. US8105600 (2009).
   Google Scholar
• The International Aids Vaccine Initiative (IAVI). Producing immune response by administering to a mammal a purified antibody–antigen complex dissociated from polyclonal anti-HIV sera bound to glycoprotein spikes on HIV envelopes, or mixture of broadly neutralizing antibodies and HIV. US2008102073 (2008).
   Google Scholar
• US Department of Health & Human Services. New immunogen for vaccinating against and treating HIV infection comprises HIV gap protein 41 polypeptide translationally linked to antibody fraction crystallizable receptor ligand. WO2009137632 (2009).
   Google Scholar
• Theraclone Sci Inc, The int aids vaccine initiative and scripps res inst. New isolated human monoclonal antibody that neutralizes HIV-1 virus in vitro, useful for treatment of HIV infection, is obtained by screening memory B cell cultures from a donor sample for broad neutralization activity against HIV-1 species. EP2408476 (2012).
   Google Scholar
• Scripps Res Inst. New polypeptide having a helical structure, useful for identifying or designing compounds used in diagnostic, pharmaceutical, immunogenic, immunological or vaccine compositions for detection, treatment and/or prevention of HIV infections. US2011124842 (2011).
   Google Scholar
• University of Maryland. New polypeptide selected from specific amino acid sequences is used for preventing or treating an HIV-1 infection in a subject. WO2014089152 (2014).
   Google Scholar
• University of California. Analyzing intra-patient HIV virus variation to identify amino acid residues of HIV envelope glycoproteins that affect sensitivity or resistance to neutralizing antibodies, involves testing pseudovirions obtained from patient sample. WO2010040136 (2010).
   Google Scholar
• US Department of Health and Human Services. Vaccine used for eliciting desired antibody against HIV antigen and cancer antigen comprises primary immunogen have intermediate degree of somatic mutational diversity, and secondary immunogen contains epitope of desired target antibody. WO2010042919 (2010).
   Google Scholar
• Rockefeller University and California Institute of Technology. Composition used for preventing or treating an HIV infection or an HIV-related disease, comprises anti-CD4 binding site potent VRC01-like antibody composition. US9890207 (2018).
   Google Scholar
• Novartis Ag. Composition, useful to treat viral infections e.g. HIV and infections caused by e.g. hepatitis-B, human papilloma virus and bovine viral diarrhea virus, comprises a glycoconjugate containing sugar moieties bound to a multivalent support. WO2011036560 (2011).
   Google Scholar
• Zhou T, Georgiev I, Wu X, et al. Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science. 2010;329(5993):811–817.
   PubMed Web of Science ®Google Scholar
• Havenar-Daughton C, Lindqvist M, Heit A, et al. CXCL13 is a plasma biomarker of germinal center activity. Proc Natl Acad Sci U S A. 2016;113(10):2702–2707.
   PubMed Web of Science ®Google Scholar
• Lynch RM. Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection. Sci Transl Med. 2015;7(319):319ra206.
   PubMed Web of Science ®Google Scholar
• Xu L, Pegu A, Rao E, et al. Trispecific broadly neutralizing HIV antibodies mediate potent SHIV protection in macaques. Science. 2017;358(6359):85–90.
   PubMed Web of Science ®Google Scholar
• Possas C, Antunes A, Mendes F, et al. Access to new technologies in multipatented vaccines: challenges for Brazil. Nat Biotechnol. 2015;33(6):599–603.
   PubMed Web of Science ®Google Scholar
• Havenar-Daughton C Lee JH, Crotty S. Tfh cells and HIV bnAbs, an immunodominance model of the HIV neutralizing antibody generation problem. Immunol Rev Immunol Rev. 2017;275(1):49–61.
   PubMed Web of Science ®Google Scholar
• Stover J, Bollinger L, Hecht R, et al. The impact of an AIDS vaccine in developing countries: a new model and initial results. Health Aff. 2007;26(4):1147–1158.
   Web of Science ®Google Scholar
• Fonseca MGP, Forsythe S, Menezes A, et al. Modeling HIV vaccines in Brazil: assessing the impact of a future HIV vaccine on reducing new infections, mortality and number of people receiving ARV. PLoS One. 2010;5(8). DOI:10.1371/annotation/4fd10061-5a1e-4164-833e-34943a74301c.
   Google Scholar